WRN inhibitors (Ryvu Therapeutics)

N/A

Report date: 2025/03/20 10:09:21
NME

Base Information

Drug NameWRN inhibitors (Ryvu Therapeutics)
Drug Alias NameWerner syndrome helicase protein inhibitors (Ryvu Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN inhibitors
TargetsBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPoland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesRyvu Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A